Clinical Trials

Clinical Trials

Enrolling

  1. A Phase 3,  Randomized,  3-Part Study To Investigate The Efficacy And Safety Of Dupilumab In Adult And Adolescent Patients With Eosinophilic Esophagitis. -Sponsor: Regeneron
  2. A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-reported Outcomes in Pediatric and Adult Patients with Eosinophilic Esophagitis (EoE), Gastritis (EG), and Colitis (EC) – Sponsor: NIH (U54- CEGIR)
  3. A Phase 3,  Randomized,  3-Part Study To Investigate The Efficacy And Safety Of Dupilumab In Adult And Adolescent Patients With Eosinophilic Esophagitis. -Sponsor: Regeneron
  4. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients with Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (formerly referred to as Eosinophilic Gastroenteritis) Who Have an Inadequate Response with, Lost Response to, or Were Intolerant to Standard Therapies                                    -Sponsor: Allakos
  5. Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects with Eosinophilic Esophagitis            -Sponsor: Adare
  6. A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients with Active Eosinophilic Esophagitis     – Sponsor: Regeneron
  7. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA)         – Sponsor:AstraZeneca
  8. Validation of The Food Frequency Questionnaire (FFQ) for EGIDs                              – Sponsor: Icahn School of Medicine
  9. Prevalence of feeding dysfunction in children with eosinophilic esophagitis (EoE)       – Sponsor: Icahn School of Medicine

 

Active but closed for enrollment

  1. A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) with Eosinophilic Esophagitis Sponsor: Shire
  2. Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet followed by Swallowed GlucocorticoidSponsor: NIH (U54- CEGIR)
  3. Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) followed by Swallowed Glucocorticoid Trial (CEGIR 7802) – Sponsor: NIH (U54- CEGIR)
  1. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients with Eosinophilic Gastritis with or without Eosinophilic Gastroenteritis Sponsor: Allakos
  2. A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients with Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis-Sponsor: Allakos

 

Completed

  1. A Randomized,  Double-Blind,  Parallel,  Placebo-Controlled Study of the Efficacy,  Safety and Tolerability of Dupilumab in Adult Patients with Active Eosinophilic Esophagitis Sponsor: Regeneron
  2. Development,  validation and evaluation of an adult and pediatric eosinophilic esophagitis activity index- A prospective multicenter study. Sponsor: University of Bern, Switzerland
  1. Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Sponsor: Ception Therapeutics
  2. A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55 mg/kg, 2.5 mg/kg or 10 mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years (Study MEE103219). Sponsor: GlaxoSmithKline